Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including pulsed field ablation, tavr, cardiac rhythm management, diabetes, spine, and neuromodulation galway, ireland , may 21, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced financial results for its fourth quarter (q4) and fiscal year 2025 (fy25), which ended april 25, 2025. q4 key highlights q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organic q4 gaap diluted eps of $0.82 increased 67%; non-gaap diluted eps of $1.62 increased 11% q4 operating margin increased 380 basis points; q4 non-gaap operating margin increased 90 basis points q4 operating profit of $1.4 billion increased 36%; q4 non-gaap operating profit of $2.5 billion increased 8% cardiac ablation solutions q4 revenue increased nearly 30% on strength of pulsed field ablation (pfa) products; business delivered $1.0 billion in fy25 revenue submitted hugo™ ras system to the u.s. food and drug administration (fda) for a urologic indication in the first quarter of calendar 2025 commenced largest brain-computer interface launch following u.s. fda approval of brainsense™ adaptive deep brain stimulation (adbs) additional key highlights fy25 revenue of $33.5 billion, adjusted revenue of $33.6 billion, increased 3.6% as reported and 4.9% organic fy25 gaap diluted eps of $3.61 increased 31%; non-gaap diluted eps of $5.49 increased 6% fy25 operating margin increased 190 basis points; fy25 non-gaap operating margin increased 10 basis points, 100 basis points constant currency fy25 operating profit of $6.0 billion increased 16%; fy25 non-gaap operating profit of $8.7 billion increased 5%, 9% constant currency fy25 cash from operations of $7.0 billion; fy25 free cash flow of $5.2 billion company returned $6.3 billion to shareholders in fy25 dividend for q1 fy26 increased to $0.71 per share, implying annual $2.84 per share; 48th consecutive year of dividend increases announced today intent to separate diabetes business into new standalone public company q4 financial results medtronic reported q4 worldwide revenue of $8.927 billion, an increase of 3.9% as reported and 5.4% on an organic basis.
MDT Ratings Summary
MDT Quant Ranking